Propanc Biopharma (PPCB) highlighted preclinical data for PRP showing >90% tumor growth inhibition in PDAC models, reduced metastases, and >2.5-fold survival extension. The company plans a Phase 1b study in Q1 2027.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
